Build

TB4 / TB500 Deep Dive — Tissue Repair, the TB4-vs-TB500 Distinction, and vs BPC-157

4 min read

TB4 / TB500 Deep Dive — Tissue Repair & the TB4-vs-TB500 Distinction

Provenance: educational study-synthesis (secondary source)

Strong human safety data (incl. IV trials) but no long-term post-course human data; efficacy is mostly animal + a few human trials (skin/eye/heart). Not FDA-approved for these uses. [educational]; research/educational use only. Source: YouTube — vvBAsQBji0A (Thorough structured capture; full verbatim not stored.)

Key correction: TB4 ≠ TB500

  • TB4 (thymosin β4) = the full 43-amino-acid peptide; a beta-thymosin (cellular structure/repair) — distinct from alpha-thymosins (Thymosin Alpha-1, thymulin) which are immune-specific. Beta-thymosins occur in every nucleated cell; TB4 is the most abundant + most researched.
  • TB500 = only the 7-aa actin-binding fragment (aa 17–23, “LKKTETQ”) of TB4 — so it has some of TB4’s effects but misses the rest. TB4 studies don’t translate 1:1 to TB500, and TB4 is likely stronger.
  • Verdict: choose TB4 over TB500 — almost all the tissue-healing evidence uses TB4, and TB500 alone has little evidence it even works.

TB4’s multi-segment mechanism

  • aa 17–23 (the TB500 segment): binds G-actin → stabilises actin building blocks → cell migration + angiogenesis (endothelial cells move to line new vessels). Core repair mechanism.
  • First 4 aa: anti-inflammatory + anti-scar. First 15 aa: ↑cell survival / anti-apoptosis. Plus antimicrobial activity and gene/signaling activation (segments unknown).

Studied benefits (mostly TB4)

  • Skin/superficial wounds (best human data): phase-2 (73 pts) accelerated chronic-wound healing by ~1 month; topical 0.03% gel daily up to 3 mo.
  • Eye: phase-3 (18 pts) corneal healing 60% vs 13% placebo; improves moderate-severe dry eye; 0.1% solution 4–6×/day up to 28 d.
  • Heart: mouse post-MI structure/function/survival; small human study (10 pts) — TB4-pretreated stem cells → +50% heart function, +14% walking distance vs untreated stem cells.
  • Musculoskeletal: mouse fracture (+25% stiffer bone, +41% force to refracture); muscle repair 2–3× faster, dose-dependent.
  • Brain (mouse): stroke & TBI → better functional outcomes (blood-vessel remodeling, neuron growth, cell protection).

Safety & the cancer concern

Better human safety data than BPC (phase-1 IV up to 1,260 mg/day ×14 d; topical ×3 mo; 6-mo animal 2×/wk) — only minor effects, no toxicities — but no long-term post-course data. Main theoretical risk = cancer promotion, via the same repair mechanisms: angiogenesis, cell migration / epithelial-mesenchymal transition (→ invasion/metastasis), anti-apoptosis, and anti-ferroptosis (cancer-cell survival under oxidative/iron stress). The creator rates TB4 as possibly slightly more cancer-risk than BPC-157. Avoid with any cancer history/family history/precancerous lesion; screen (colonoscopy, PSA, mammogram/pap, chest CT if prior smoker, skin checks) before use; short-term targeted use only, never indefinite/preventive.

TB4 vs BPC-157 (when to use which)

  • Skin/eye: TB4 first (human evidence), add BPC if needed.
  • Heart attack: TB4 first (has human data BPC lacks); realistically both together short-term.
  • Musculoskeletal: BPC-157 wins (far more/stronger animal data; also lower cancer risk) → BPC alone for minor chronic injuries; add TB4 only if healing plateaus; for acute major injuries / post-surgery / stroke / major TBI, start both together (TB4 is an early repair signal). They’re synergistic — TB4 works via actin/structure, BPC via NO/VEGF angiogenesis.

Forms, dose, timing, cycles

  • Forms: topical (skin/eye), SubQ for MSK/cardiac/neuro. No oral — unlike acid-resistant BPC, TB4 isn’t orally bioavailable (no oral studies; avoid oral products).
  • Dose (SubQ, hypothetical): anchored to human IV-safety data (5 mcg/kg) → SubQ ≈ 7.14 mcg/kg → ~500 mcg/day for a 70 kg adult; up to 1 mg if needed.
  • Frequency: TB4 daily (half-life ~1.5 h); TB500’s half-life is longer (metabolites ~72 h) → TB500 2–3×/week can work, but TB4 daily gives steadier levels. Optional 2×/day if dosing higher; night may be marginally better (circadian repair).
  • Cycle: 4–6 weeks on / ≥6 weeks off (shorter than BPC, given higher cancer-risk framing); targeted use, stop when healed; daily is fine (no 5-on/2-off needed — no receptor desensitization).

Sourcing

Compounding pharmacies can’t legally produce TB4 now. If using research-grade anyway, demand: HPLC + mass-spec ID/purity (verify it’s the full 43-aa TB4, not TB500 mislabeled), USP<85> endotoxin, USP<71> sterility (COA/Purity). A regulated compounding pharmacy is far safer than research-use-only sources.

Candidate note reinforced

  • TB4 (Thymosin β4) as a distinct entity from TB500 — worth eventually splitting from this note; TB10/TB15 (other beta-thymosins) are minor candidates.

Graph View

Backlinks